ESMO Targeted Anticancer Therapies Congress 2025
Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Results from an interim analysis suggests the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
First-line combination of an antibody–drug conjugate plus immunotherapy shows promise in non-small cell lung cancer
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
Can AI and liquid biopsies take precision oncology to the next level?
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries